Development of Bronchopleural Fistula After Durvalumab Consolidation for Stage III Non-Small-Cell Lung Cancer

Clin Lung Cancer. 2021 Jan;22(1):e18-e24. doi: 10.1016/j.cllc.2020.07.010. Epub 2020 Jul 30.

Authors

Alicia Darwin¹, Trevor Rose², Amit Tandon³, Tawee Tanvetyanon⁴

Affiliations

¹ Morsani College of Medicine, University of South Florida, Tampa, FL. Electronic address: [email protected].
² Department of Radiology, H. Lee Moffitt Cancer Center, Tampa, FL.
³ Interventional Pulmonology, H. Lee Moffitt Cancer Center, Tampa, FL.
⁴ Thoracic Oncology Department, H. Lee Moffitt Cancer Center, Tampa, FL.

PMID: 32828661
DOI: 10.1016/j.cllc.2020.07.010

No abstract available

Keywords: Adverse event; Bronchoscopy; Immunotherapy; PD-L1.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Bronchial Fistula / chemically induced
Bronchial Fistula / pathology*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Middle Aged
Pleural Diseases / chemically induced
Pleural Diseases / pathology*
Prognosis

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
durvalumab